Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Consolidated Net Income: 2015-2025

Historic Consolidated Net Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' Consolidated Net Income fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Consolidated Net Income stood at -$19.5 million, which was up 2.72% from -$20.1 million recorded in Q2 2025.
  • Cartesian Therapeutics' Consolidated Net Income's 5-year high stood at $15.0 million during Q2 2024, with a 5-year trough of -$196.7 million in Q4 2023.
  • For the 3-year period, Cartesian Therapeutics' Consolidated Net Income averaged around -$30.7 million, with its median value being -$18.0 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 5,505.67% in 2022, then crashed by 3,437.15% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Consolidated Net Income (Quarterly) stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then slumped by 3,437.15% to -$196.7 million in 2023, then soared by 87.66% to -$24.3 million in 2024, then plummeted by 30.10% to -$19.5 million in 2025.
  • Its Consolidated Net Income stands at -$19.5 million for Q3 2025, versus -$20.1 million for Q2 2025 and -$19.9 million for Q1 2025.